{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:04:14Z","timestamp":1789769054339,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.htct.2026.106537","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:50:40Z","timestamp":1789768240000},"page":"106537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Central nervous system recurrence of diffuse large B-cell lymphoma \u2013 risk stratification and prophylaxis"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1541-7952","authenticated-orcid":false,"given":"Thamiris Silva","family":"Soares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-9507","authenticated-orcid":false,"given":"Daniel Dias","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.htct.2026.106537_bib0001","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.htct.2026.106537_bib0002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"issue":"26","key":"10.1016\/j.htct.2026.106537_bib0003","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.htct.2026.106537_bib0004","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3324\/haematol.2020.266635","article-title":"Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom","volume":"106","author":"Roschewski","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.htct.2026.106537_bib0005","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1016\/S1470-2045(22)00371-0","article-title":"CNS prophylaxis for diffuse large B-cell lymphoma","volume":"23","author":"Eyre","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.htct.2026.106537_bib0006","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-018-0569-2","article-title":"Central nervous system prophylaxis strategies in diffuse large B cell lymphoma","volume":"19","author":"Kansara","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"10.1016\/j.htct.2026.106537_bib0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3324\/haematol.2018.195834","article-title":"Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma","volume":"104","author":"Qualls","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.htct.2026.106537_bib0008","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.2021014043","article-title":"CNS prophylaxis in DLBCL: time to say goodbye?","volume":"139","author":"Schmitz","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2026.106537_bib0009","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ejh.12763","article-title":"Central nervous system prophylaxis in diffuse large B-cell lymphoma","volume":"97","author":"Zahid","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.htct.2026.106537_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-023-00467-2","article-title":"Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma","volume":"13","author":"Chua","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"10.1016\/j.htct.2026.106537_bib0011","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy","volume":"21","author":"Villa","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.htct.2026.106537_bib0012","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural history of CNS relapse in patients with aggressive non-Hodgkin\u2019s lymphoma: a 20-year follow-up analysis of SWOG 8516\u2014Southwest Oncology Group","volume":"27","author":"Bernstein","year":"2009","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.htct.2026.106537_bib0013","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German high-grade non-hodgkin lymphoma study group (DSHNHL)","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.htct.2026.106537_bib0014","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3324\/haematol.2019.229948","article-title":"Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review","volume":"105","author":"Eyre","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.htct.2026.106537_bib0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.clml.2015.02.026","article-title":"Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis - A systematic review of prospective studies","volume":"15","author":"Ghose","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.htct.2026.106537_bib0016","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ajh.26181","article-title":"Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma","volume":"96","author":"Puckrin","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.htct.2026.106537_bib0017","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3324\/haematol.2022.281457","article-title":"Prevention and management of secondary central nervous system lymphoma","volume":"108","author":"Bobillo","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.htct.2026.106537_bib0018","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-021-00506-3","article-title":"Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse","volume":"11","author":"Bobillo","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.htct.2026.106537_bib0019","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021012888","article-title":"Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions","volume":"139","author":"Orellana-Noia","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.htct.2026.106537_bib0020","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2021014506","article-title":"Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients","volume":"139","author":"Wilson","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.htct.2026.106537_bib0021","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2014.405","article-title":"A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma","volume":"111","author":"Cheah","year":"2014","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.htct.2026.106537_bib0022","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3892\/mco.2022.2592","article-title":"Outcomes of high-dose methotrexate for CNS prophylaxis in diffuse large B-cell lymphoma with an intermediate or high CNS-international prognostic index: a single-center retrospective cohort study","volume":"17","author":"Al-Mansour","year":"2022","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"10.1016\/j.htct.2026.106537_bib0023","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","article-title":"High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology","volume":"105","author":"Hegde","year":"2005","journal-title":"Blood"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926002841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926002841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:50:47Z","timestamp":1789768247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137926002841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2531137926002841"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2026.106537","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central nervous system recurrence of diffuse large B-cell lymphoma \u2013 risk stratification and prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2026.106537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}],"article-number":"106537"}}